Consistent with the lack of effects of CNS GLP-1 on fat mass, we also failed to detect any significant change in the expression of several key enzymes regulating lipid metabolism in WAT. Schematic overview summarizing the pharmacological effects of CNS GLP-1 on fat tissue. It has captivated interest due to its incretin (aiding the action of insulin) and anorectic effects (Turton et al., 1996; Holst, 2007). The GLP-1 analog, Exendin-4 (EX4), a highly selective GLP-1 receptor (GLP-1R) agonist (Thorens et al., 1993) is a rapidly emerging novel diabetes treatment. It is now also evaluated as a potential obesity treatment due to its beneficial effects to reduce food intake and body weight. Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. To our knowledge, this is the first report documenting the potential effects of CNS GLP-1 on adipocyte lipid metabolism. The present experiments have confirmed that activation of the CNS GLP-1 system can decrease food intake and body weight (Tang-Christensen et al., 1996, 1998; Meeran et al., 1999; Rodriquez de Fonseca et al., 2000). The decrease in body weight is consistent with the observed lower amount of fat mass after central GLP-1 infusion.

Visit my blog post :: ColonBroom